| 738.34 42.92 (6.17%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 864.32  |
1-year : | 1009.52 |
| Resists | First : | 740 |
Second : | 864.32 |
| Pivot price | 673.75 |
|||
| Supports | First : | 665.65 |
Second : | 619.7 |
| MAs | MA(5) : | 690.42 |
MA(20) : | 670.87 |
| MA(100) : | 689.83  |
MA(250) : | 680.12 |
|
| MACD | MACD : | 14.8 |
Signal : | 9.1 |
| %K %D | K(14,3) : | 94.8 |
D(3) : | 79.1 |
| RSI | RSI(14): 74.4 |
|||
| 52-week | High : | 818.9 | Low : | 538.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ REGN ] has closed above the upper band by 24.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 28.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 740.44 - 742.63 | 742.63 - 745.08 |
| Low: | 688.57 - 691.14 | 691.14 - 694.03 |
| Close: | 733.56 - 737.65 | 737.65 - 742.23 |
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Thu, 30 Jul 2026
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts - finance.yahoo.com
Thu, 30 Jul 2026
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Thu, 30 Jul 2026
Regeneron Pharmaceuticals Inc (REGN) (Q2 2026) Earnings Call Hig - GuruFocus
Thu, 30 Jul 2026
Regeneron Pharmaceuticals Q2 Earnings Call Highlights - TradingView
Thu, 30 Jul 2026
Regeneron Pharmaceuticals Crushes Q2 2026 Profit Estimates - AlphaStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 94.3 (%) |
| Shares Short | 3,500 (K) |
| Shares Short P.Month | 3,300 (K) |
| EPS | 40.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 308.32 |
| Profit Margin | 29.6 % |
| Operating Margin | 20.6 % |
| Return on Assets (ttm) | 6.1 % |
| Return on Equity (ttm) | 14.5 % |
| Qtrly Rev. Growth | 19 % |
| Gross Profit (p.s.) | 63.57 |
| Sales Per Share | 144.82 |
| EBITDA (p.s.) | 42.51 |
| Qtrly Earnings Growth | -7.2 % |
| Operating Cash Flow | 5,010 (M) |
| Levered Free Cash Flow | 3,270 (M) |
| PE Ratio | 18.03 |
| PEG Ratio | 1.1 |
| Price to Book value | 2.39 |
| Price to Sales | 5.09 |
| Price to Cash Flow | 15.18 |
| Dividend | 0.93 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|